Loading…
← CockpitCompetitor Analysis › PTCT PTC Therapeutics, Inc.Open in the cockpit ↗

PTC Therapeutics, Inc.PTCTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech selling small-molecule and gene-therapy drugs for rare genetic diseases, including spinal muscular atrophy and Duchenne muscular dystrophy.

Momentum weak 35
Mkt cap
$5.03B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$67.4M
20-day average traded
Fwd P/E
31.2×
forward earnings
ROIC−WACC
n/a
WACC 7.4%
Hurdle
-29 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · USD$60.23
1D-0.2%
1W-7.2%
1M-4.3%
3M-14.6%
6M-15.2%
YTD-20.7%
1Y-20.3%
ATR %4.0%
Beta0.84
52w lowhigh33.7% off high

What PTC Therapeutics does

Biotech selling small-molecule and gene-therapy drugs for rare genetic diseases, including spinal muscular atrophy and Duchenne muscular dystrophy.

Combines sales of its own rare-disease drugs, priced for very small patient groups and sold through specialty pharmacies, with royalties from Roche's Evrysdi, a spinal muscular atrophy drug it helped discover, which arrive without selling costs. It has sold part of that royalty stream to Royalty Pharma, and the rest helps fund its pipeline.

Products and services

  • Evrysdi royalties (SMA, with Roche)
  • Emflaza/Translarna (Duchenne muscular dystrophy)
  • Upstaza (gene therapy, AADC deficiency)

Customers

  • Neurologists/geneticists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Rare genetic/neuromuscular disease

What could go right

  • Evrysdi royalty growth as Roche expands access
  • Gene-therapy pipeline maturing toward approval

What could go wrong

  • Reliance on royalty income from a partnered drug
  • High-cost gene-therapy manufacturing/reimbursement risk

Moat: narrow (IP / patents, regulatory licence). Deep rare-neuromuscular-disease expertise and orphan exclusivity across a diversified genetic-disease portfolio.

Headquarters: Warren, New Jersey, United States · Founded: 1998 · Employees: 991

Named competitors

PTC Therapeutics at a glance

Size PTC Therapeutics (PTCT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.03B, the 1170th largest of 3,085 United States companies the cockpit tracks. Shares closed at $60.23 on 18 Nov 2026.

Performance Over six months the shares fell 15.2%, against +10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue fell 35.0% over the last twelve months (peer median +12.1%); the operating margin is 21.6% (peer median 20.6%).

Valuation It trades at 31.2× forward earnings against a peer median of 25.8× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -29 pp: the price already allows for a slowdown.

Short interest Short interest is 9.3% of the free float (30 Oct 2026).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 112PTCT 86
Six months, rebased to 100: PTC Therapeutics against the median of its 20 peers (local-currency closes).

PTC Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.16B$1.73B$807M$938M$699M
Revenue growth—+115%-14%+34%—
Gross profit$1.03B$1.66B$689M$650M$538M
EBITDA$310M$895M-$71.1M-$113M-$311M
Net income-$106M$683M-$363M-$627M-$559M
Free cash flow$2.07M$702M-$114M-$187M-$389M
Capital expenditure$51.8M$300M$74.2M$121M$152M
Total debt$636M$399M$389M$415M$704M

Quarterly statements and history in the cockpit →

PTC Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%326030IPCALABLQDA600085600079ERASTVTXMANEGLAXO688578EMCUREIONS6030870874GLANDAJANTPHARMABBOTINDIA600566CAMXPTCT6-month return →1-month return →
Up and to the right = strong over both horizons. PTC Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×326030IPCALABLQDA600085600079TVTXGLAXO6885784506EMCURE6030870874GLANDCAMXPTCTRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PTC Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%326030IPCALABLQDA600085600079688578PTCTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PTC Therapeutics is the large dot.

PTC Therapeutics competitors and peer comparison

Head to head with its named competitors (PTCT vs SRPT vs RO.SW vs BIIB)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
PTC Therapeutics PTCT$5.03B-15%-35%22%31.2×6.6%
Sarepta Therapeutics SRPT$1.56B-15%-19%0%n/a-6.8%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Biogen BIIB$37.2B+34%+2%17%17.1×10.1%

How PTC Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PTC Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasurePTCTPeer medianRank in peer set
1-month return-4.3%+0.2%7th lowest of 21
6-month return-15.2%+10.6%4th lowest of 21
Distance from 52-week high-33.7%-21.1%8th lowest of 21
Revenue growth (TTM)-35.0%+12.1%lowest of 19
Operating margin21.6%20.6%9th highest of 19
Forward P/E31.2×25.8×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)6.6%6.5%9th least demanding of 17
Growth delivered (Del g)+35.4%+12.5%5th highest of 17
Hurdle (Req g minus delivered)-28.7 pp-2.6 pp5th least demanding of 17
EV / EBITDA11.4×22.8×cheapest of 11
Net debt / EBITDA-4.8×-0.7×least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%

Questions

Who are PTC Therapeutics's main competitors?
Named competitors: Sarepta Therapeutics (SRPT), Roche (RO.SW), Biogen (BIIB). The cockpit's measured peer set (industry) also includes SKBP (326030.KS), IPCA Laboratories (IPCALAB.NS), Liquidia (LQDA), Beijing TongRenTang (600085.SS), Humanwell Healthcare (Group) (600079.SS), Erasca (ERAS).
Is PTC Therapeutics expensive compared with its peers?
On forward p/e it trades at 31.2× against a peer median of 25.8×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -29 pp: the price already allows for a slowdown.
How has PTC Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -15.2% against +10.6% for the median peer; over one year -20.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.